Biotech RadarJobs updated

COMPANY

Arrowhead Pharmaceuticals

HQ: Pasadena, CA source · arrowheadpharma.com ↗ · West Coast

FDA-approved therapeutic company Clinical Phase 3

85 open jobs · last seen Oct 23, 2026 · 53 sources

Keywords: RNA therapeutics Severe Hypertriglyceridemia Homozygous Familial Hypercholesterolemia Hypertriglyceridemia Asthma Familial Chylomicronemia Hepatitis B Chronic Hepatitis B Alpha-1 Antitrypsin Deficiency Obesity IgA Nephropathy Dyslipidemias Mixed Dyslipidemia Metabolic Dysfunction-Associated Steatohepatitis Alzheimer Disease Early Onset Alzheimer Disease Age-related Macular Degeneration Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Type 2 Diabetes Mellitus Spinocerebellar Ataxia Type 2 C3 Glomerulopathy High Risk Severe Hypertriglyceridemia (SHTG) Hepatitis D Familial Hypercholesterolemia Pulmonary Cystic Fibrosis Clear Cell Renal Cell Carcinoma Non-alcoholic Steatohepatitis Amyotrophic Lateral Sclerosis Plozasiran ARO-APOC3 ARC-520 ARO-INHBE Zodasiran ARO-033 ARO-MUC5AC

Profile checked Oct 10, 2026

85Open jobs50Trials (company is sponsor)1FDA records (2 yrs)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Analyst II, Cyber Security (Operational Technology)Madison, Wisconsin, United States; Pasadena, California, United States; San Diego, California, United States; Verona, Wisconsin, United StatesOct 22, 2026Oct 23, 2026
Senior Director, Medical CapabilitiesPasadena, California, United StatesOct 21, 2026Oct 22, 2026
Manager, Commercial Technology & Digital SolutionsPasadena, California, United StatesOct 20, 2026Oct 21, 2026
Associate Engineer I, ValidationVerona, Wisconsin, United StatesOct 20, 2026Oct 21, 2026
Manager, TaxPasadena, California, United StatesOct 20, 2026Oct 21, 2026

See all 85 jobs

Trial and FDA signals

Job counts as of Oct 18, 2026. All trial and FDA signals

Raises and deals from press releases

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Board tracked Radar started tracking this company’s job board (85 open jobs at last check). source ↗
  2. Trial start Phase 1: A First-In-Human Study of ARO-033 in Adult Participants source ↗
  3. Trial start Phase 2: Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma source ↗
  4. Debt Debt: $625M (not counted as a raise), announced Jan 7, 2026. Source: SEC filing. source ↗
  5. Trial start Phase 1/Phase 2: Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia source ↗
  6. FDA FDA New drug/biologic (novel): REDEMPLO (plozasiran sodium) — NDA219947, Nov 18, 2025. Applicant at approval: Arrowhead Pharmaceuticals, Inc. source ↗
  7. Trial start Phase 1/Phase 2: Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease source ↗
  8. Partnership Partnership / licensing: $200M (upfront, as published), announced Sep 2, 2025. Source: SEC filing. source ↗
  9. Trial start 3: A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) source ↗
  10. Trial start Phase 1/Phase 2: A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus source ↗
  11. Trial start Phase 3: Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis source ↗
  12. Trial start Phase 3: Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia source ↗
  13. Trial start Phase 1: Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 source ↗
  14. Trial start Phase 1/Phase 2: A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus source ↗
  15. Trial start Phase 3: Study of Plozasiran in Adults With Severe Hypertriglyceridemia source ↗
  16. Trial start Phase 3: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia source ↗
  17. Trial start 3: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia source ↗
  18. Trial start Phase 1: Study of ARO-CFB in Adult Healthy Volunteers source ↗
  19. Trial start Phase 1/Phase 2: Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis source ↗
  20. Trial start Phase 1: Study of ARO-RAGE in Healthy Subjects source ↗
  21. Trial start Phase 2: Study of ARO-APOC3 in Adults With Dyslipidemia source ↗
  22. Trial start Phase 1/Phase 2: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease source ↗
  23. Trial start Phase 3: Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia source ↗
  24. Trial start Phase 2: A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis source ↗
  25. Trial start Phase 1: Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) source ↗

Showing 25 of 53 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 85

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Analyst II, Cyber Security (Operational Technology)Madison, Wisconsin, United States; Pasadena, California, United States; San Diego, California, United States; Verona, Wisconsin, United StatesOct 22, 2026Oct 23, 2026Not stated
Senior Director, Medical CapabilitiesPasadena, California, United StatesOct 21, 2026Oct 22, 2026Not stated
Manager, Commercial Technology & Digital SolutionsPasadena, California, United StatesOct 20, 2026Oct 21, 2026Not stated
Associate Engineer I, ValidationVerona, Wisconsin, United StatesOct 20, 2026Oct 21, 2026Not stated
Manager, TaxPasadena, California, United StatesOct 20, 2026Oct 21, 2026Not stated
Forward Deployed Engineer, AIMadison, Wisconsin, United States; Pasadena, California, United States; San Diego, California, United States; Verona, Wisconsin, United StatesOct 20, 2026Oct 21, 2026Not stated
Senior Data Platform EngineerMadison, Wisconsin, United States; Pasadena, California, United States; San Diego, California, United States; Verona, Wisconsin, United StatesOct 20, 2026Oct 21, 2026Not stated
Senior Clinical Research AssociateSan Diego, California, United StatesOct 20, 2026Oct 21, 2026Not stated
Associate Scientist II, Quality ControlVerona, Wisconsin, United StatesOct 19, 2026Oct 20, 2026Not stated
Senior Quality Specialist, CAPA InvestigationsVerona, Wisconsin, United StatesOct 19, 2026Oct 20, 2026Not stated
Health Outcomes Liaison - EastRemoteOct 16, 2026Oct 17, 2026Not stated
Scientist III, Discovery Chemistry (Peptide Synthesis)San Diego, California, United StatesOct 15, 2026Oct 16, 2026Not stated
Health Outcomes Liaison - CentralRemoteOct 15, 2026Oct 17, 2026Not stated
Associate Director, Medical Value, Evidence, and Outcomes (MVEO)Pasadena, California, United StatesOct 14, 2026Oct 15, 2026Senior
Senior Manager, Medical PublicationsPasadena, California, United StatesOct 14, 2026Oct 15, 2026Senior
Senior Scientist I, Discovery PharmacologyMadison, Wisconsin, United StatesOct 14, 2026Oct 15, 2026Senior
Associate Director, Sales TrainingRemoteOct 13, 2026Oct 14, 2026Senior
Director, Contracts & PricingPasadena, California, United States; RemoteOct 9, 2026Oct 9, 2026Senior
Senior Manager, Integrated Quality OperationsVerona, Wisconsin, United StatesOct 9, 2026Oct 9, 2026Senior
Senior Manager, Early Phase Quality OperationsVerona, Wisconsin, United StatesOct 9, 2026Oct 9, 2026Senior
Specification Lead, Quality OperationsVerona, Wisconsin, United StatesOct 7, 2026Oct 9, 2026Senior
Associate Manufacturing Scientist IVerona, Wisconsin, United StatesOct 6, 2026Oct 9, 2026Entry
Senior Specialist, Supplier QualityPasadena, California, United States; San Diego, California, United StatesOct 5, 2026Oct 9, 2026Senior
Senior Manager, Medical Device Quality/Product ComplaintsVerona, Wisconsin, United StatesOct 5, 2026Oct 9, 2026Senior
Associate Scientist I, In Vivo ResearchMadison, Wisconsin, United StatesOct 2, 2026Oct 9, 2026Mid
Equipment Engineering Co-OpVerona, Wisconsin, United StatesSep 29, 2026Oct 9, 2026Entry
Associate Director, Manufacturing Science and TechnologyVerona, Wisconsin, United StatesSep 25, 2026Oct 9, 2026Senior
Team Leader, Raw MaterialsVerona, Wisconsin, United StatesSep 18, 2026Oct 9, 2026Senior
Engineer I, Process ValidationVerona, Wisconsin, United StatesSep 18, 2026Oct 9, 2026Entry
Senior Manager, Analytical DevelopmentVerona, Wisconsin, United StatesSep 17, 2026Oct 9, 2026Senior
Associate Scientist I, Discovery Chemistry OperationsMadison, Wisconsin, United StatesSep 14, 2026Oct 9, 2026Entry
Scientist I, Early Phase Process DevelopmentVerona, Wisconsin, United StatesSep 14, 2026Oct 9, 2026Entry
Lead, Technical TransferVerona, Wisconsin, United StatesSep 9, 2026Oct 9, 2026Senior
Senior Specialist, EHSMadison, Wisconsin, United StatesSep 8, 2026Oct 9, 2026Senior
Senior Director, Quality ControlVerona, Wisconsin, United StatesSep 8, 2026Oct 9, 2026Senior
Manager, Regulatory AffairsPasadena, California, United States; San Diego, California, United StatesSep 8, 2026Oct 9, 2026Mid
Associate Director, Corporate Financial Planning & AnalysisPasadena, California, United States; San Diego, California, United StatesSep 8, 2026Oct 9, 2026Senior
Senior Manager, Analytical Method ValidationVerona, Wisconsin, United StatesSep 3, 2026Oct 9, 2026Senior
Associate Director, National AccountsRemoteSep 1, 2026Oct 9, 2026Senior
Senior Quality Specialist, Supplier QualityVerona, Wisconsin, United StatesAug 27, 2026Oct 9, 2026Senior
Director, Regulatory Affairs (Labeling)Pasadena, California, United States; San Diego, California, United StatesAug 25, 2026Oct 9, 2026Senior
National Account Director (Optum & Emisar)RemoteAug 24, 2026Oct 9, 2026Senior
National Account Director (Government Payers)RemoteAug 24, 2026Oct 9, 2026Senior
National Account Director (Zinc/ Caremark)RemoteAug 24, 2026Oct 9, 2026Senior
Quality Specialist III, Document Control and TrainingVerona, Wisconsin, United StatesAug 24, 2026Oct 9, 2026Mid
Senior Scientist I, Discovery Chemistry (Synthetic Chemistry)Madison, Wisconsin, United StatesAug 24, 2026Oct 9, 2026Senior
Metrology Technician llVerona, Wisconsin, United StatesAug 24, 2026Oct 9, 2026Mid
Senior Accountant, SEC ReportingPasadena, California, United StatesAug 21, 2026Oct 9, 2026Senior
Medical Science LiaisonRemote, Outside USAAug 18, 2026Oct 9, 2026Mid
Associate Director, External ManufacturingVerona, Wisconsin, United StatesAug 18, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

All 85 jobs →

Funding

Debt: $625.0M. Last 2 years.

Clinical trials (lead sponsor) 50

RecordTitlePhaseStatusStartPrimary completion
NCT06347016Study of Plozasiran in Adults With Severe HypertriglyceridemiaPhase 3CompletedJul 23, 2024Jun 17, 2026 (actual)
NCT06347003Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaPhase 3CompletedJul 22, 2024Jun 12, 2026 (actual)
NCT07859813A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated SteatohepatitisPhase 2Not yet recruiting2026-092029-10 (estimated)
NCT07473843Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaPhase 3Recruiting2026-102028-07 (estimated)
NCT06822790Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaPhase 3Active, not recruitingApr 9, 20252028-07 (estimated)
NCT07241546Study of Inhaled ARO-RAGE in Allergen-induced Mild AsthmaPhase 2RecruitingMar 30, 20262027-12 (estimated)
NCT06700538A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusPhase 1/Phase 2RecruitingDec 4, 2024Sep 17, 2027 (estimated)
NCT06347133Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia3CompletedMay 21, 2024Jun 1, 2026 (actual)
NCT06880770Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisPhase 3RecruitingApr 24, 20252029-03 (estimated)
NCT07221344Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's DiseasePhase 1/Phase 2RecruitingNov 18, 20252027-06 (estimated)
NCT07662096A First-In-Human Study of ARO-033 in Adult ParticipantsPhase 1RecruitingJun 25, 2026Jul 1, 2028 (estimated)
NCT05292950Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseasePhase 1/Phase 2TerminatedJun 27, 2022Nov 12, 2024 (actual)
NCT07223658Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaPhase 1/Phase 2RecruitingDec 22, 2025Sep 30, 2026 (estimated)
NCT07037771A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)3Active, not recruitingJun 17, 2025Aug 20, 2027 (estimated)
NCT05537025Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary FibrosisPhase 1/Phase 2CompletedJan 30, 2023Sep 5, 2025 (actual)
NCT06937203A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusPhase 1/Phase 2RecruitingMay 9, 20252027-02 (estimated)
NCT06672445Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2Phase 1Active, not recruitingDec 17, 20242026-12 (estimated)
NCT05217667Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)Phase 2TerminatedApr 22, 2022May 2, 2023 (actual)
NCT05089084Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)Phase 3CompletedDec 14, 2021Apr 29, 2024 (actual)
NCT05083364Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseasePhase 1/Phase 2CompletedFeb 1, 2022Sep 10, 2025 (actual)
NCT06209177Study of ARO-CFB in Adult Healthy VolunteersPhase 1CompletedApr 5, 2024Mar 31, 2025 (actual)
NCT05413135Study of ARO-APOC3 in Adults With DyslipidemiaPhase 2CompletedJul 7, 2022Sep 22, 2025 (actual)
NCT04998201Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaPhase 2CompletedSep 28, 2021Feb 10, 2023 (actual)
NCT05276570Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseasePhase 1/Phase 2CompletedJun 29, 2022Apr 16, 2025 (actual)
NCT04720534Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaPhase 2CompletedMay 31, 2021Mar 9, 2023 (actual)
NCT06796426Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCSNot listedAvailableNot listedNot listed
NCT02577029Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)Phase 2Terminated2015-122016-12 (actual)
NCT02065336A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionPhase 2Terminated2014-032017-01 (actual)
NCT02604199A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) InfectionPhase 2Terminated2015-092017-01 (actual)
NCT02738008Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) InfectionPhase 2Terminated2016-032016-12 (actual)
NCT02535416A Study of ARC-520 at Varying Infusion Rates in Healthy Adult VolunteersPhase 1Completed2015-092016-08 (actual)
NCT02604212A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionPhase 2Terminated2015-112016-12 (actual)
NCT02363946A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)Phase 1Terminated2015-022016-11 (actual)
NCT02797522A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)Phase 1Terminated2016-062016-11 (actual)
NCT02349126Study of ARC-520 in Patient With Chronic Hepatitis B VirusPhase 2Withdrawn2015-022015-12 (estimated)
NCT01872065Safety and Tolerability Study of ARC-520 in Healthy VolunteersPhase 1Completed2013-072014-09 (actual)
NCT03783377Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)Phase 1CompletedMar 8, 2019Feb 11, 2021 (actual)
NCT03747224Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic PatientsPhase 1CompletedJan 7, 2019May 17, 2021 (actual)
NCT03362242Study of ARO-AAT in Normal Adult VolunteersPhase 1CompletedMar 12, 2018Oct 23, 2018 (actual)
NCT02900183Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin LevelsPhase 2Withdrawn2016-102016-11 (actual)
NCT04375514Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic FibrosisPhase 1/Phase 2TerminatedJul 30, 2020May 9, 2021 (actual)
NCT04832971Study of ARO-ANG3 in Adults With Mixed DyslipidemiaPhase 2CompletedJun 28, 2021Aug 30, 2022 (actual)
NCT03945292Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)Phase 2CompletedAug 7, 2019Nov 8, 2021 (actual)
NCT02452528Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusPhase 2Terminated2015-082016-12 (actual)
NCT03365947Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)Phase 1/Phase 2CompletedMar 27, 2018Apr 23, 2020 (actual)
NCT03946449Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)Phase 2CompletedOct 31, 2019Apr 28, 2022 (actual)
NCT04169711Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell CarcinomaPhase 1CompletedAug 17, 2020Jan 24, 2022 (actual)
NCT04202354Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASHPhase 1/Phase 2CompletedMar 3, 2020Sep 3, 2021 (actual)
NCT05949294Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)Phase 1Withdrawn2024-012025-03 (estimated)
NCT05533294Study of ARO-RAGE in Healthy SubjectsPhase 1CompletedNov 29, 2022Feb 8, 2024 (actual)

FDA records (last 2 years)

Connect

See your connections at Arrowhead Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12

Feedback